Impact of developmental pharmacology on pediatric study design: overcoming the challenges.
about
Pharmacokinetics of isoniazid in low-birth-weight and premature infants.Decision Making for Postpartum Depression TreatmentShort sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.Dosing in neonates: special considerations in physiology and trial design.Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African MothersEvaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria.Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsAdverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.Neonatal pharmacology: extensive interindividual variability despite limited size.Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective.Challenges Associated with Route of Administration in Neonatal Drug Delivery.Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies.Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective.Differences between adolescents and adults in the acute effects of PCP and ketamine and in sensitization following intermittent administration.Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
P2860
Q33622922-FEA0DA55-1D05-4C64-A656-C2079961CF24Q34285105-DD853E3F-4F91-44C6-A538-6B82EC7F9B83Q34311035-BABA05AD-8EAC-4AD8-82B2-318A1775D380Q34716879-ADDC3B6A-44B6-419B-9A18-CA8E521A0A6EQ35130521-A0CE9B97-FEC0-4E76-B264-B700C7448DBBQ36644625-3D5C08AF-4FA4-48B2-8294-98E70170FE17Q37108173-951F1C05-C89B-49FD-B6A0-E5D23B871007Q37378093-E583AE4E-1D85-44F0-918C-C31827E1A9CFQ37872784-8D2A39D5-FE75-4A2E-B27C-DA94337DDEBAQ38000252-2848C1A3-29AE-45C3-A524-01FC3998BE67Q38245572-F243CBAC-EE51-41AB-BCA1-525E84CD192DQ38561363-3C9912F9-3313-4D22-9384-5A5F75619F7DQ38747217-52C10886-CED2-487E-BB7A-A0BFFDF7BA3AQ46401505-122BFB79-A438-4108-A5C3-0050A4DB4AE0Q46530600-57AB56BC-A151-4BE3-9EDA-B4F721734BC6Q46736444-92706668-71A1-4FD4-A5BB-37B0DC9B380FQ47428031-879D79BA-AAF1-4CBE-B3BF-66732505F625Q55454780-ED9E8BBA-FDC3-4A94-889C-DFFDDE50D246
P2860
Impact of developmental pharmacology on pediatric study design: overcoming the challenges.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Impact of developmental pharma ...... gn: overcoming the challenges.
@ast
Impact of developmental pharma ...... gn: overcoming the challenges.
@en
Impact of developmental pharma ...... gn: overcoming the challenges.
@nl
type
label
Impact of developmental pharma ...... gn: overcoming the challenges.
@ast
Impact of developmental pharma ...... gn: overcoming the challenges.
@en
Impact of developmental pharma ...... gn: overcoming the challenges.
@nl
prefLabel
Impact of developmental pharma ...... gn: overcoming the challenges.
@ast
Impact of developmental pharma ...... gn: overcoming the challenges.
@en
Impact of developmental pharma ...... gn: overcoming the challenges.
@nl
P356
P1476
Impact of developmental pharma ...... gn: overcoming the challenges.
@en
P2093
P304
P356
10.1067/MAI.2000.109419
P407
P433
P577
2000-09-01T00:00:00Z